During the past decade, Stockton Hematology Oncology Medical Group conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 4 clinical trials were completed, i.e. on average, 133.3% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Stockton Hematology Oncology Medical Group" #1 sponsor was "Achieve Life Sciences" with 1 trials, followed by "Agennix" with 1 trials sponsored, "Bristol-Myers Squibb" with 1 trials sponsored, "CTI BioPharma" with 1 trials sponsored and "Celgene" with 1 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Stockton Hematology Oncology Medical Group" #1 collaborator was "Eli Lilly and Company" with 1 trials as a collaborator, "ICON Clinical Research" with 1 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator and "National Cancer Institute (NCI)" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Stockton Hematology Oncology Medical Group" are "Multiple Myeloma" (3 trials), "Breast Cancer" (2 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials), "Prostate Cancer" (2 trials) and "Advanced Breast Cancer" (1 trials). Many other conditions were trialed in "Stockton Hematology Oncology Medical Group" in a lesser frequency.

Most popular intervention types in "Stockton Hematology Oncology Medical Group" are "Drug" (10 trials), "Biological" (2 trials), "Diagnostic Test" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Bortezomib" (1 trials), "Dexamethasone" (1 trials), "Freenome Test" (1 trials) and "Melphalan" (1 trials). Other intervention names were less common.

The vast majority of trials in "Stockton Hematology Oncology Medical Group" are 12 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Stockton Hematology Oncology Medical Group". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Stockton Hematology Oncology Medical Group, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Stockton Hematology Oncology Medical Group, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".